Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.2797
Abstract: PD(L)1 antibodies (anti‐PD(L)‐1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti‐PD(L)‐1. We aimed at characterizing pseudoprogression (PSPD) among patients with various solid… read more here.
Keywords: tumor types; patients treated; evidence pseudoprogression; pseudoprogression ... See more keywords
Exploring the Limitations of Virtual Contrast Prediction in Brain Tumor Imaging: A Study of Generalization Across Tumor Types and Patient Populations
Sign Up to like & getrecommendations! Published in 2025 at "NMR in Biomedicine"
DOI: 10.1002/nbm.70062
Abstract: Accurate and timely diagnosis of brain tumors is critical for patient management and treatment planning. Magnetic resonance imaging (MRI) is a widely used modality for brain tumor detection and characterization, often aided by the administration… read more here.
Keywords: brain; contrast; patient populations; tumor types ... See more keywords
Tumors in the cauda equina: A SEER analysis of tumor types and predictors of outcome
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Neuroscience"
DOI: 10.1016/j.jocn.2020.09.068
Abstract: Caudaequinatumors are histologically diverse. International Classification of Diseases for Oncology (ICD-O3) confers dedicated site code (C72. 1) for cauda equina. This code is excluded during analyses of other primary spinal cord tumors. In this retrospective… read more here.
Keywords: tumor types; age; analysis; cauda equina ... See more keywords
Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients
Sign Up to like & getrecommendations! Published in 2017 at "Nature medicine"
DOI: 10.1038/nm.4333
Abstract: Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of genomic alterations in genes and pathways that can be targeted therapeutically. The existence of recurrent targetable alterations across distinct histologically defined… read more here.
Keywords: tumor types; clinical sequencing; 000 patients; cancer ... See more keywords
Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
Sign Up to like & getrecommendations! Published in 2024 at "Nature Medicine"
DOI: 10.1038/s41591-024-02934-7
Abstract: Fibroblast growth factor receptor (FGFR) alterations drive oncogenesis in multiple tumor types. Here we studied pemigatinib, a selective, potent, oral FGFR1–FGFR3 inhibitor, in the phase 2 FIGHT-207 basket study of FGFR-altered advanced solid tumors. Primary… read more here.
Keywords: response; fgfr1 fgfr3; basket; tumor types ... See more keywords
Gene fusions in superficial mesenchymal neoplasms: Emerging entities and useful diagnostic adjuncts.
Sign Up to like & getrecommendations! Published in 2023 at "Seminars in diagnostic pathology"
DOI: 10.1053/j.semdp.2023.04.014
Abstract: Cutaneous mesenchymal neoplasms are diagnostically challenging because of their overlapping morphology, and, often, the limited tissue in skin biopsy specimens. Molecular and cytogenetic techniques have identified characteristic gene fusions in many of these tumor types,… read more here.
Keywords: cell; mesenchymal neoplasms; gene fusions; tumor ... See more keywords
Divergent evolutionary dynamics of benign and malignant tumors
Sign Up to like & getrecommendations! Published in 2025 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.2519203122
Abstract: Benign and malignant (cancerous) tumors differ markedly in their impact on organismal fitness, yet studies in comparative oncology rarely distinguish between them. Using a Bayesian phylogenetic framework across birds and mammals, we show that while… read more here.
Keywords: oncology; benign malignant; tumor types; prevalence ... See more keywords
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study.
Sign Up to like & getrecommendations! Published in 2024 at "Future oncology"
DOI: 10.1080/14796694.2024.2367957
Abstract: Aim: To determine the prevalence of deleterious mutations in BRCA1 and BRCA2 and in 13 genes involved in homologous recombination repair (HRR), the prevalence of genomic loss of heterozygosity and the allelic and hereditary status… read more here.
Keywords: observational study; tumor; homologous recombination; tumor types ... See more keywords
Pattern of MUC6 expression across 119 different tumor types: A tissue microarray study on 15 412 tumors.
Sign Up to like & getrecommendations! Published in 2023 at "Pathology international"
DOI: 10.1111/pin.13322
Abstract: Mucin 6 (MUC6) is a secreted gel-forming mucin covering the surfaces of gastrointestinal and other tissues. Published work demonstrates that MUC6 can also be expressed in several cancer types and can aid in the distinction… read more here.
Keywords: tumor types; muc6 expression; tumor; different tumor ... See more keywords
Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression
Sign Up to like & getrecommendations! Published in 2021 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-002680
Abstract: Introduction Several studies have shown clinical outcomes data that support the use of CD274 (PD-L1) copy-number (CN) gains and/or losses as a biomarker for immune checkpoint inhibitor (ICPI). Here, we present the landscape of CD274… read more here.
Keywords: tumor types; cd274 changes; 244 584; cd274 ... See more keywords
Abstract A008: PDX-based screen to evaluate and compare approved CDK4/6 inhibitors in breast cancer and determine palbociclib efficacy in additional tumor types
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-a008
Abstract: Background: FDA-approved CDK 4/6 inhibitors (CDK4/6i) including palbociclib, abemaciclib, and ribociclib have demonstrated clinical benefit in treating hormone receptor-positive (HR+) breast cancer. However, whether there is differential sensitivity to each therapy in vivo is unknown.… read more here.
Keywords: palbociclib; tumor types; cancer; breast cancer ... See more keywords